Similar articles

• Extracorporeal treatment of erythrocytes in sickle cell anemia: hemoglobin carbamylation.

  Diederich D, Curran M, Odenbaugh A, Diederich A, Core E. Diederich D, et al. Tex Rep Biol Med. 1980-1981;40:313-22. Tex Rep Biol Med. 1980. PMID: 7323976 No abstract available.
• Understanding antisickling agents and the sickling process.

  Godwin M, Baysinger M. Godwin M, et al. Nurs Clin North Am. 1983 Mar;18(1):207-14. Nurs Clin North Am. 1983. PMID: 6550864 No abstract available.
• Physiologic and rheologic effects of the antisickling agent ethacrynic acid and its N-butylated derivative on normal and sickle erythrocytes.

  Orringer EP, Blythe DS, Whitney JA, Brockenbrough S, Abraham DJ. Orringer EP, et al. Am J Hematol. 1992 Jan;39(1):39-44. doi: 10.1002/ajh.2830390109. Am J Hematol. 1992. PMID: 1536139
• Clinical Pharmacology for Pediatricians. II. Antisickling agents, with special reference to new vasoerythroactive drugs.

  Cho YW, Aviado DM. Cho YW, et al. J Clin Pharmacol. 1982 Jan;22(1):1-13. doi: 10.1002/j.1552-4604.1982.tb05701.x. J Clin Pharmacol. 1982. PMID: 7037870 Review. No abstract available.
• Established and experimental treatments for sickle cell disease.

  De Franceschi L, Corrocher R. De Franceschi L, et al. Haematologica. 2004 Mar;89(3):348-56. Haematologica. 2004. PMID: 15020275 Review.